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Abstract Mast cell activation disease (MCAD) is a term re-
ferring to a heterogeneous group of disorders characterized by
aberrant release of variable subsets of mast cell (MC) media-
tors together with accumulation of either morphologically al-
tered and immunohistochemically identifiable mutated MCs
due toMC proliferation (systemic mastocytosis [SM] andMC
leukemia [MCL]) or morphologically ordinary MCs due to
decreased apoptosis (MC activation syndrome [MCAS] and
well-differentiated SM). Clinical signs and symptoms in
MCAD vary depending on disease subtype and result from
excessive mediator release by MCs and, in aggressive forms,
from organ failure related to MC infiltration. In most cases,
treatment of MCAD is directed primarily at controlling the
symptoms associated with MC mediator release. In advanced
forms, such as aggressive SM and MCL, agents targeting MC
proliferation such as kinase inhibitors may be provided.
Targeted therapies aimed at blocking mutant protein variants
and/or downstream signaling pathways are currently being
developed. Other targets, such as specific surface antigens
expressed on neoplastic MCs, might be considered for the
development of future therapies. Since clinicians are often
underprepared to evaluate, diagnose, and effectively treat this
clinically heterogeneous disease, we seek to familiarize clini-
cians with MCAD and review current and future treatment
approaches.
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Introduction
Mast cells (MCs, Fig. 1) are immune cells of hematopoietic
origin found in all human tissues, especially at the environ-
mental interfaces. They act as both effector and regulatory
cells and play a central role in adaptive and innate immunity
(Anand et al. 2012; Gri et al. 2012). Their important role in
immunological as well as non-immunological processes is
reflected by the large number of mediators (>200) including
pre-stored ones such as histamine and tryptase as well as nu-
merous mediators synthesized de novo in response to allergic
or non-immune triggers such as chemokines and cytokines, by
which MCs may influence other cells (Lundequist and Pejler
2011; Ibelgaufts 2016). Their evolved arrays of sensory and
response mechanisms engender diverse havoc when MC dys-
function emerges.
The umbrella term mast cell activation disease (MCAD;
Akin et al. 2010) comprises the full spectrum of primary sys-
temic MC disease, i.e., systemic mastocytosis (SM) which is
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further divided into several subtypes (Valent et al. 2007;
Tables 1 and 2), primary MC activation syndrome (MCAS;
Table 3; Molderings et al. 2011a; Hamilton et al. 2011; Valent
et al. 2012), and MC leukemia (MCL). Pathogenetically,
MCAD denotes a group of polygenic MC disorders
(Molderings 2015, 2016) characterized by aberrant release
of variable subsets of MCmediators and also an accumulation
of either morphologically altered and immunohistochemically
identifiable mutated MCs due to MC proliferation (SM and
MCL) or morphologically ordinary MCs due to decreased
apoptosis (MCAS; Kohno et al. 2005; Aichberger et al.
2009; Karlberg et al. 2010a). According to recent molecular
genetic findings (Molderings 2015, 2016; Haenisch et al.
2014; Lasho et al. 2016), the subclasses and clinical subtypes
of MCAD do not represent distinct disease entities but should
be more accurately regarded as variable presentations of a
common generic state of MC dysfunction (Molderings et al.
2007, 2010; Hermine et al. 2008; Akin et al. 2010). Due to
both the widespread distribution of MCs and the great hetero-
geneity of aberrant mediator expression patterns, symptoms
can occur in virtually all organs and tissues; hence, the clinical
presentation ofMCAD is very diverse, sometimes to the even-
further-confounding point of presenting opposite abnormali-
ties in different patients (or even in the same patient at differ-
ent times, or in different sites in the same patient at the same
time). While the prevalence of SM in Europeans ranges be-
tween 0.3 and 13 per 100,000 (Haenisch et al. 2012; Cohen
et al. 2014; van Doormaal et al. 2013), the prevalence of
MCAS may be as high as 17 % (in Germany; Molderings
et al. 2013a, b).
This review focuses on the current state of drug therapy in
SM and MCAS and describes perspectives of promising new
approaches for drug treatment. Compounds in various stages
of preclinical and clinical development are summarized in
tables. We first describe drugs that are currently available
and either are used on a regular basis in MCAD therapy or
have been used successfully in single MCAD cases. In this
context, it should be noted that there is no official guideline for
treatment of MCAD.
Treatment options
Due to its genetic roots, MCAD generally is regarded as in-
curable. Recent mutational studies revealed that each patient
has an individual pattern of genetic and epigenetic alterations
which may affect the intracellular signal transduction path-
ways and receptive sites involved in sensory perception. As
a consequence, mediator formation and release as well as in-
hibition of apoptosis and/or increase in proliferation are deter-
mined by individual genetic and epigenetic conditions (Fig. 2)
and represent potential targets for therapy. Hence, there is
need of highly personalized therapy for the disease.
Unfortunately (with regard to easy detection), most genetic
alterations (with a few exceptions such as certain mutations
Fig. 1 May-Grünwald/Giemsa stain of a resting human mast cell
and a mast cell following activation-induced degranulation. Note the
loss of granule staining. Mast cells obtained from the human bone
marrow, magnification 1000×
Table 1 WHO 2008 diagnostic criteria for systemic mastocytosis
(Valent et al. 2001)
Major criterion:
1. Multifocal, dense aggregates of MCs (15 or more) in sections of the
bonemarrow or other extracutaneous tissues and confirmed by tryptase
immunohistochemistry or other special stains
Minor criteria:
1. Atypical or spindled appearance of at least 25 % of the MCs in the
diagnostic biopsy
2. Expression of CD2 and/or CD25 by MCs in the marrow, blood, or
extracutaneous organs
3. KIT codon 816 mutation in the marrow, blood, or extracutaneous
organs
4. Persistent elevation of serum total tryptase >20 ng/ml
Diagnosis of SM made by either (1) the major criterion plus any one of
the minor criteria or (2) any three minor criteria
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in tyrosine kinase KIT, e.g., KITD816V) do not alter the mor-
phology and immunohistochemistry of the surface of the af-
fected MCs. Thus, in most cases except for patients with the
reliably identifiable D816V mutation, it cannot be decided by
simple tests whether MCs found in biopsies are genetically
altered MCs or physiological MCs.
First-line treatment options
Step 1 in managing most situations of inappropriate MC acti-
vation is identifying the individual patient’s unique triggers
(chemical, physical, or otherwise) as precisely as possible
and then desensitizing when possible (in truth, rarely) and
otherwise practicing avoidance. With respect to drug treat-
ment, only a few clinical therapeutic trials have been
conducted in SM (midostaurin, cladribine, masitinib; Table
4), and there have been no therapeutic trials in MCAS yet.
Most information about therapeutic effectiveness in MCAD
has been found in small case series (Table 4) and single case
reports, perhaps unsurprising given the mutational heteroge-
neity of the disease and thus the heterogeneity of its patterns of
clinical presentation and therapeutic responsiveness.
Therefore, in the future, it may be helpful to establish an in-
ternational patient registry in partnership with existing regis-
tries so that issues related to molecular and clinical MCAD
phenotypes can be adequately addressed. As the primary fea-
ture of MCAD is inappropriate MC activation (Molderings et
al. 2011a, b; Pardanani 2013; Cardet et al. 2013), mainstays of
first-line management are identification and avoidance of trig-
gers plus therapies to control MC mediator production (both




Occasional patients suffer nearly continuous anaphylactoid
and/or dysautonomic states poorly controlled by intermittently
dosed epinephrine, antihistamines, and steroids. As discussed
in more detail below, some such patients are particularly trig-
gered by a wide range of medication excipients, making it
challenging for them to tolerate trials of any adulterated
(non-pure) medications, and yet some modicum of stability
is required to pursue medication trials in such patients.
Table 3 Current provisional criteria to define mast cell activation syndrome (MCAS; modified from Afrin and Molderings 2014)
Major criterion
Constellation of clinical complaints attributable to pathologically increased mast cell activity (mast cell mediator release syndrome)
Minor criteria
1. Focal or disseminated increased number of mast cells in marrow and/or extracutaneous organ(s) (e.g., gastrointestinal tract biopsies; CD117-,
tryptase-, and CD25-stained)
2. Abnormal spindle-shaped morphology in >25 % of mast cells in marrow or other extracutaneous organ(s)
3. Abnormal mast cell expression of CD2 and/or CD25 (i.e., co-expression of CD117/CD25 or CD117/CD2)
4. Detection of genetic changes in mast cells from the blood, bone marrow, or extracutaneous organs for which an impact on the state of activity of
affected mast cells in terms of an increased activity has been proven
5. Evidence (typically from body fluids such as whole blood, serum, plasma, or urine) of above-normal levels of mast cell mediators including:
• Tryptase in the blood
• Histamine or its metabolites (e.g., N-methylhistamine) in the urine
• Heparin in the blood
• Chromogranin A in the blood (potential confounders of cardiac or renal failure, neuroendocrine tumors, or recent proton pump inhibitor use were
excluded)
• Other relatively mast cell-specific mediators (e.g., eicosanoids including prostaglandin PGD2, its metabolite 11-β-PGF2α, or leukotriene E4)
6. Symptomatic response to inhibitors of mast cell activation or mast cell mediator production or action (e.g., histamine H1 and/or H2 receptor
antagonists, cromolyn)
Diagnosis of MCAS made by either (1) the major criterion plus any one of the minor criteria or (2) any three minor criteria
individual mutation pattern
specific constitutive activity
of affected mast cells 
systemic endogenous 





mast cell activty 
individual symptomatology
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Fig. 2 Scheme of conditions responsible in MCAD for the development
of individual phenotypes
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Diphenhydramine is a well-tolerated histamine H1 receptor
blocker (that among other non-threatening adverse affects
can cause dizziness and an increase in appetite) which can
quickly suppress MC activation and is used to treat allergic
reactions and anaphylaxis. However, its half-life is as short as
1 h (www.drugbank.ca/drugs/DB01075). Intermittently
dosed, though, its initial therapeutic serum level rapidly
declines to subtherapeutic levels and the patient seesaws into
yet another flare. The safety of continuous diphenhydramine
infusion was established in trials of the BBAD^ regimen
(diphenhydramine [Benadryl], lorazepam [Ativan], and
dexamethasone) in refractory chemotherapy-induced emesis
in adult and pediatric patients (Dix et al. 1999; Jones et al.
2007). In a small series of tenMCAS patients suffering almost
continuous anaphylactoid/dysautonomic flares, continuous
diphenhydramine infusion at 10–14.5mg/h appeared effective
in most patients at dramatically reducing flare rates and ap-
peared safely sustainable at stable dosing for at least 21months
(Afrin 2015). Stabilization has enabled successful trials of
other helpful medications, but no patient has yet successfully
stopped continuous diphenhydramine infusion.
Table 4 Case series and clinical therapeutic trials in systemic








Rupatadine 30 Siebenhaar et al. 2013
Azelastine vs.
chlorpheniramine
15 Friedman et al. 1993
Ketotifen vs.
hydroxyzine
8 Kettelhut et al. 1989
Chlorpheniramine plus
cimetidine








5 Soter et al. 1979
11 Horan et al. 1990
4 Mallet et al. 1989
8 Frieri et al. 1985
2 Welch et al. 1983
2 Zachariae et al. 1981
Tranilast 2 Katoh et al. 1996
Kinase inhibitors
Imatinib (STI571) 14 Droogendijk et al. 2006
20 Vega-Ruiz et al. 2009
22 Lim et al. 2009
17 Pagano et al. 2008
12 Pardanani et al. 2003
5 Heinrich et al. 2008
3 Hennessy et al. 2004
Nilotinib (AMN107) 61 Hochhaus et al. 2015
Dasatinib (BMS-354825) 33 Verstovsek et al. 2008
4 Purtill et al. 2008
Midostaurin (PKC412) 9 Papayannidis et al. 2014
11 Knapper et al. 2011
22 Chandesris et al. 2014
89 Gotlib et al. 2014
14 Strati et al. 2015
Masitinib 25 Paul et al. 2010
Cytostatic agents




22 Lim et al. 2009
10 Kluin-Nelemans et al.
2003
4 Pardanani et al. 2004
3 Pagano et al. 2008









Interferon-α 20 Casassus et al. 2002
5 Hauswirth et al. 2004
10 Laroche et al. 2011
40 Lim et al. 2009
8 Pagano et al. 2008
6 Giraldo Castellano et al.
1998
9 Hennessy et al. 2004
3 Worobec et al. 1996
Thalidomide 16 Gruson et al. 2013
IgE antibody
Omalizumab 4 Molderings et al. 2011ba
2 Carter et al. 2007
2 Lieberoth and Thomsen
2015
ß-Sympathomimetics
Isoprenaline, terbutaline 5 van Doormaal et al. 1986
Cyclooxygenase inhibitor
Acetylsalicylic acid 4 Butterfield and Weiler
2008
20 Butterfield 2009
a It indicates clinical trials performed with patients with mast cell
activation syndrome
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Acute and chronic immunosuppressive therapies
Though typically not first-line, acute and chronic immunosup-
pressive therapies can be considered (Fig. 3; Table 7) and may
be particularly appropriate for patients possibly manifesting
an autoimmune component of the disease as might be sug-
gested by the presence, for example, of anti-IgE or anti-IgE-
receptor antibodies. Glucocorticoids may exert beneficial ef-
fects in MCAD, including a decrease in production of stem
cell factor (SCF, and possibly other cytokines) and a decrease
in MC activation, by various mechanisms which have been
extensively reviewed by Oppong et al. 2013. Glucocorticoids
at doses >20 mg prednisone equivalent per day are frequently
needed to effectively control otherwise refractory acute (and
chronic) symptoms. Their chronic toxicity profile is disadvan-
tageous for long-term use, but such toxicities have to be ac-
cepted in some cases. The influence of azathioprine, metho-
trexate, ciclosporine, hydroxyurea, and tamoxifen on MC ac-
tivity can vary from no to moderate effect depending on indi-
vidual disease factors. As in therapy of rheumatoid arthritis,
azathioprine and methotrexate can be used in daily doses
lower than those used in cancer or immunosuppressive post-
transplant therapy. EffectiveMCAD therapy with ciclosporine
requires doses as high as those used in transplantation medi-
cine (M. Raithel, personal communication). Methotrexate has
to be administered parenterally to be effective (unpublished
observation, G.J. Molderings), and in the risk-benefit analysis,
a possible non-immunologic histamine release from MCs
(Estévez et al. 1996) has to be considered. Hence, use of the
compound should be limited to MCAD with methotrexate-
sensitive comorbidities (e.g., rheumatoid arthritis and
vasculitis).
Recently, the humanized anti-IgE murine monoclonal anti-
body omalizumab has been described in multiple case reports
as safe and effective in MCAD (e.g., Molderings et al. 2011b;
Kontou-Fili et al. 2010; Bell and Jackson 2012; Kibsgaard
et al. 2014), though a definitive trial has yet to be conducted.
Since treatment with omalizumab has an acceptable risk-
benefit profile, it should be considered in cases of MCAD
resistant to at least a few lines of therapy. The drug’s expense
likely consigns it to third-line (or later) treatment (Table 7). If
elevated prostaglandin levels induce symptoms such as
Table 5 First-line drugs which can potentially be used in the treatment ofmast cell (MC) activation disease and their target location andmechanisms of
action









of the second and third generations)




X X Church and Gradidge
1980
Valent et al. 2007R
Picard et al. 2013R
Nurmatov et al. 2015
Siebenhaar et al. 2013
Escribano et al. 2006R
H2-antihistamines Block mutual activation of mast cells
via H2-histamine receptors; antagonize
H2-histamine receptor-mediated
symptoms
X X Valent et al. 2007R
Escribano et al. 2006R
Cromoglicic acid (also known
as cromolyn)
GPR35; modulation of chloride current X X Soter et al. 1979
Valent et al. 2007R
Yang et al. 2010
Edwards et al. 2011
Edwards and Hagberg
2010
Zhang et al. 2016
Escribano et al. 2006R
Vitamin C Increased degradation of histamine;
decrease of histamine formation by
inhibition of histidine decarboxylase
X X Hagel et al. 2013
Johnston et al. 1992
Uchida et al. 1989
Chatterjee et al. 1975
As a rule, these drugs should be used in combination to achieve a sufficient reduction of MC activity. All drugs should be tested for tolerance in a low
single dose before therapeutic use, if their tolerance in the patient is not known from an earlier application. A precondition for therapeutic success is the
avoidance of identifiable triggers of MC activation; in this context, parallel to the beginning of drug therapy, gluten, cow milk protein, and baker’s yeast
should be omitted from the diet for 3–4 weeks
R review article (further references therein)
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persistent flushing, inhibition of cyclooxygenases by incre-
mental doses of acetylsalicylic acid (ASA; 50–350 mg/day)
may be used with extreme caution, since ASA can induce MC
degranulation probably due its chemical property as an organ-
ic acid. The leukotriene antagonist montelukast (possibly
more effective at twice-daily dosing; personal observation,
Table 6 Symptomatic treatment (orally as needed) in MCAD (modified from Molderings et al. 2014)
Colitis ⇒ budesonide; for some days, prednisone >20 mg/day
Diarrhea⇒ c(h)olestyramine; nystatin; montelukast; 5-HT3 receptor inhibitors (e.g. ondansetron); incremental doses of acetylsalicylic acid (50–350 mg/
day; extreme caution because of the possibility to induce mast cell degranulation); in steps test each drug for 5 days until improvement of diarrhea
Colicky abdominal pain due to distinct meteorism ⇒ metamizole; butylscopolamine
Angioedema ⇒ tranexamic acid; icatibant
Nausea ⇒ dimenhydrinate; lorazepam; 5-HT3 receptor inhibitors; NK1 antagonists such as aprepitant
Respiratory symptoms (mainly due to increased production of viscous mucus and obstruction with compulsive throat clearing) ⇒ leukotriene receptor
blockers such as montelukast; if in a country available, leukotriene synthesis inhibitors such as zileuton; urgent: short-acting ß-sympathomimetic
Gastric complaints ⇒ proton-pump inhibitors (de-escalating dose-finding)
Osteoporosis, osteolysis, bone pain ⇒ bisphosphonates (vitamin D plus calcium application is second-line treatment in MCAD patients because of
limited reported success and an increased risk for developing kidney and ureter stones); calcitonin; teriparatide (with caution; cases of cholestatic liver
failure due to this drug have been reported); anti-RANKL drugs such as denosumab (dental clearance is required prior to treatment with
bisphosphonates and anti-RANKL therapies due to risk for potentially severely morbid osteonecrosis of the jaw in patients with poor dentition or
recent invasive dental work)
Non-cardiac chest pain⇒when needed, additional dose of a H2-histamine receptor antagonist; also, proton-pump inhibitors for proven gastroesophageal
reflux
Tachycardia ⇒ AT1-receptor antagonists; ivabradine
Neuropathic pain and paresthesia ⇒ α-lipoic acid
Itches ⇒ palmitoylethanolamine-containing care products; cromolyn-containing ointment
Rheumatoid symptoms ⇒ COX2 inhibitors such as etoricoxib or celecoxib; paracetamol
Anemia ⇒ in iron-deficiency anemia, iron supplementation (whether oral or parenteral) must be given cautiously due to risk for potentially intense mast
cell activation; alternatively, red blood cell transfusion should be considered
Interstitial cystitis ⇒ pentosan, amphetamines
Sleep-onset insomnia/sleep-maintenance insomnia ⇒ triazolam
Conjunctivitis ⇒ exclusion of a secondary disease; otherwise preservative-free eye drops with H1-antihistamine, cromolyn, ketotifen, or glucocorticoid
for brief courses
Hypercholesterolemia ⇒ (probably due to inhibition of transport into the cells, thus independent of diet) >300 mg/dL therapeutic trial with HMG-CoA
reductase inhibitor atorvastatin
Fig. 3 Suggested treatment
options for mast cell activation
disease. All drugs should be
tested for tolerance in a low single
dose before therapeutic use, if
their tolerance in the patient is not
known from an earlier
application. For further details of
indication, see text
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L.B. Afrin) and the 5-lipoxygenase inhibitor zileuton may be
useful adjuvants in people with MCAD, particularly in those
with refractory gastrointestinal and urinary symptoms (Tolar
et al. 2004; Turner et al. 2012; Akhavein et al. 2012).
Studies of kinase inhibitors, both on-market (e.g., imatinib,
nilotinib, dasatinib) and experimental (e.g., midostaurin,
masitinib), have yielded variable responses in SM ranging
from no response to partial or even complete responses
(Fig. 3; Table 8). As with all drugs used in therapy of
MCAD, their therapeutic success seems to be strongly depen-
dent on the individual patient, again underscoring the ob-
servedmutational heterogeneity of the disease. In formal stud-
ies in SM patients, although some kinase inhibitors reduced
MC burden as reflected by histological normalization in bone
marrow and improved laboratory surrogate markers (e.g.,
tryptase level in blood), at best only partial improvement of
mediator-related symptoms was achieved (Droogendijk et al.
2006; Gotlib et al. 2008; Verstovsek et al. 2008; Vega-Ruiz et
al. 2009). There has been repeated suggestion that symptoms
in MCAD may be due more to mediator release from normal
MCs secondarily activated by pathologically overactive, mu-
tated MCs (Galli and Costa 1995; Rosen and Goetzl 2005;
Boyce 2007; Kaneko et al. 2009; Fig. 2 in Molderings et al.
2014), helping to explain why intensity and pattern of symp-
toms do not correlate with degree of MC proliferation and
infiltration (Topar et al. 1998; Hermine et al. 2008; Broesby-
Olsen et al. 2013; Erben et al. 2014; Quintás-Cardama et al.
2013). Distinction in pathways in the MC which promote MC
proliferation vs. mediator production/release may explain why
kinase inhibitors reduce MC burdens and MC-driven symp-
toms to different degrees (Droogendijk et al. 2006; Gotlib et
al. 2008; Verstovsek et al. 2008; Vega-Ruiz et al. 2009; Table
8). However, in some case reports, kinase inhibitors have
been significantly effective at relieving symptoms. Thus,
in spite of potential serious adverse effects of these drugs,
a therapeutic trial may be justified in individual cases at
an early stage. Partial and complete responses have been
reported with some of these agents in MCAS too (e.g.,
Afrin 2010, 2011, 2012, 2015; Afrin et al. 2015a). Dosing
of the kinase inhibitors in the individual often is consid-
erably lower than how such drugs are dosed for other
applications (e.g., imatinib, sunitinib; Afrin et al. 2015a).
Possibly due to the causative mutations in multiple genes
leading to simultaneous activation of multiple intracellular
pathways, multitargeted kinase inhibitors such as
midostaurin and sunitinib may be more effective than








To relieve symptoms References
Second-line drugs Immunosuppressive drugs
Azathioprine Multiple targets X X Nolte and Stahl Skov 1988, Own
unpublished data
Ciclosporine Calcineurin inhibitor X X Kurosawa et al. 1999, Broyd et al. 2005,
Trojan and Khan 2012, Own
unpublished data
Glucocorticoids Multiple targets (X) X X Zen et al. 2011R
Hydroxyurea Multiple targets X X Lim et al. 2009, Afrin 2013
Tamoxifen Precise mechanism of action
in MCAD unknown
X X In single cases Butterfield and Chen 2016, Duffy et al.
2003;
Methotrexate Multiple targets ? X Sagi et al. 2011, Vrugt et al. 2000
Third-line drugs
Omalizumab Anti-IgE antibody X Molderings et al. 2011b
Bell and Jackson 2012; Kibsgaard et al.
2014
Kontou-Fili et al. 2010
Etoricoxib
Acetylsalicylic acid
COX-inhibitors X Butterfield and Weiler 2008
Breslow et al. 2009
Butterfield 2009
Montelukast Antagonist at cys-LT1 receptors X Tolar et al. 2004
Cikler et al. 2009
Breslow et al. 2009
Turner et al. 2012
Zileuton 5-Lipoxygenase inhibitor X Rodriguez et al. 2011
R review article (further references therein)
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drugs which selectively downregulate only one intracellu-
lar pathway.
In the mastocytosis patient with significant MC burden
and/or an aggressive clinical course, cytoreductive drugs are
prescribed (Lim et al. 2009; Valent et al. 2010). Unfortunately,
effective cytoreductive therapies in SM presently are few in
number and typically offer only modest response rates, qual-
ities, and durations. Cytoreductive options include
interferon-α and 2-chlorodeoxyadenosine (cladribine, 2-
CdA; Fig. 3 and Table 9). Interferon-α is frequently combined
with prednisone and is commonly used as cytoreductive ther-
apy for aggressive SM. It ameliorates mastocytosis-related
organopathy in a proportion of cases but can be associated
with considerable adverse effects (e.g., flu-like symptoms,
myelosuppression, depression, hypothyroidism), which may
limit its use in MCAD (Simon et al. 2004; Butterfield 2005).
PEGylated interferon-α has been shown to be as efficacious as
and less toxic than the non-PEGylated form in some myelo-
proliferative neoplasms, but it has not been specifically stud-
ied in MCAD. 2-Chlorodeoxyadenosine is generally reserved
for last-choice treatment of patients with aggressive SM who
are either refractory or intolerant to interferon-α. Potential
toxicities of 2-CdA include significant and potentially
prolonged myelosuppression and lymphopenia with increased
risk for opportunistic infections.
Last resorts
Polychemotherapy, including intensive induction regimens of
the kind used in treating acute myeloid leukemia, as well as
Table 8 Kinase inhibitors which can potentially be used as fourth-line drugs in the treatment ofmast cell activation disease and their target location and
mechanisms of action





To relieve symptoms References
Fourth-line drugs Inhibitors of tyrosine kinases and other kinases
Imatinib KIT (excluding D816X), PDGFR,
Bcr-Abl, Arg/Abl2, DDR-1
X (X) X Pardanani et al. 2003
Droogendijk et al. 2006
Lim et al. 2009
Vega-Ruiz et al. 2009
Aman et al. 2012
Vaali et al. 2012
Quintás-Cardama et al. 2011R
Marton et al. 2015
Nilotinib KIT, PDGFR, Bcr-Abl X (X) Hochhaus et al. 2006
Quintás-Cardama et al. 2011R
Hochhaus et al. 2015
El-Agamy 2012
Dasatinib KIT, BCR-ABL1, Lyn, Btk, Tec X (X) Verstovsek et al. 2008
Hantschel et al. 2007
Gleixner et al. 2011
Quintás-Cardama et al. 2011R
Sunitinib VEGFR, PDGFR, KIT, FLT3, RET,
CSF1R, SRC,
313 potential kinase targets
X X X Afrin et al. 2015a
Yamaki and Yoshino 2012
Papaetis and Syrigos 2009
Bairlein 2010
Masitinib KIT, PDGFRα, Lck, LYN, FGFR3, FAK X X Marech et al. 2014
Moussy and Kinet 2014
Paul et al. 2010
Quintás-Cardama et al. 2011R
Midostaurin PKC, FLT3, KIT, PDGFR, VEGFR2 X X X Gotlib et al. 2014
Papayannidis et al. 2014
Knapper et al. 2011
Quintás-Cardama et al. 2011R
Ponatinib Bcr-Abl, KIT, FLT3, FGFR1, PDGFRα, Lyn X Jin et al. 2014
Gleixner et al. 2013
Bafetinib KIT (excluding D816X), Abl, Lyn X Peter et al. 2010a
Bosutinib Lyn, Btk X In ASM patients ineffective Gleixner et al. 2011
Randall et al. 2015
R review article (further references therein)
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high-dose therapy with stem cell rescue, are approaches re-
stricted to rare, selected patients. Allogeneic stem cell trans-
plantation sometimes yields remissions in mastocytosis long
thought impermanent (Spyridonidis et al. 2004; Nakamura
et al. 2006; Bae et al. 2013; Gromke et al. 2013), though recent
data may offer new hope (Ustun et al. 2014).
Investigational drugs
There are several drugs approved for indications other than
MCADwhich already have been successfully used in isolated
cases withMCAD (Table 10). In cases of unsuccessful first- to
fourth-line therapy, these compounds may be considered as
treatment options.
A variety of drugs have been shown to inhibit MC growth,
to decrease MC mediator release, and/or to relieve mediator-
induced symptoms in in vitro and in vivo animal models
(Table 11). Some of these drugs are approved for certain indi-
cations (such as ambroxol, statins, mefloquine, and
ruxolitinib) and, thus, may be used (if accessible given finan-
cial considerations for some agents) if MCAD patients suffer
from both the disorder of indication (e.g., hypercholesterol-
emia—statins, mucous congestion—ambroxol, polycythemia
vera—ruxolitinib) andMCAD. An important question is what
the role of the other compounds without approved indications
should be in clinical practice. There are several challenges that
may hamper the clinical introduction of novel targeted thera-
pies in general. Some of these challenges include inherent
problems in the translation of preclinical findings to the clinic,
the presence of multiple coactive deregulated pathways in the
disease, and questions related to the optimal design of clinical
trials (e.g., eligibility criteria and endpoints). In particular, the
testing of novel targeted treatment in an isolated fashion may
be problematic and may in fact underestimate the effective-
ness of these novel compounds. It is reasonable to assume that
combination therapy will be the key to target parallel critical
pathways.
General considerations on drug treatment of MCAD
Although no biomarkers of symptomaticity or therapeutic re-
sponse are yet validated, the tolerability and efficacy of most
therapies tried in MCAD (starting, and escalating in dosage
and composition, cautiously) become clinically evident within
1–2 months. Modest experiments with alternative dosages
and/or dosing frequencies are not unreasonable. Therapies
clearly shown clinically helpful should be continued; thera-
pies not meeting this high bar should be halted to avoid the
troublesome polypharmacy that can easily develop in such
patients. With no predictors of response yet available, a cost-
based approach to sequencing therapeutic trials in a given
patient seems reasonable. It is not even clear yet that medica-
tions targeted at mediators found elevated in diagnostic testing
(e.g., antihistamines in patients with elevated histamine, non-
steroidal anti-inflammatory drugs in patients with elevated
prostaglandins, leukotriene inhibitors in patients with elevated
leukotrienes) are reliably effective, again perhaps unsurprising
given the multitude of MC mediators and the complexity of
the signaling networks dysregulated by the multiple mutations
in MC regulatory elements present in most MCAD patients.
Successful regimens appear highly personalized.
Table 9 Last-choice drugs which can potentially be used in the treatment of mast cell activation disease and their target location and mechanisms of
action. R-review article (further references therein)
Target location/mechanisms
of action






Interferon-α Multiple targets X (X) Simon et al. 2004
Casassus et al. 2002
Hauswirth et al. 2004
Butterfield et al. 2005
Butterfield 2005R
Yoshida et al. 2009
Lim et al. 2009
Quintás-Cardama et al. 2011R
Cladribine Nucleoside analog X X X Tefferi et al. 2001
Kluin-Nelemans et al. 2003
Pardanani et al. 2004
Lim et al. 2009
Böhm et al. 2010
Radojković et al. 2011
Quintás-Cardama et al. 2011R
Lock et al. 2015
Barete et al. 2015
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Multiple simultaneous (or nearly so) changes in the medi-
cation regimen are discouraged since such can confound iden-
tification of the specific therapy responsible for a given im-
provement (or deterioration). Ineffective or harmful agents
should be stopped promptly. Prescribers should be aware that
although rapid demonstration of intolerance of a new medica-
tion (or a new formulation of a previously well-tolerated med-
ication) often suggests excipient reactivity as further discussed
below, some active drug molecules themselves (e.g.,
cromolyn) sometimes cause an initial symptom flare which
usually soon abates. Temporary waiver of gluten-, yeast-, and
cowmilk protein-containing foods during the initial 3–4 weeks
of drug therapy can improve the response rate (Biesiekierski
et al. 2011; Rodrigo et al. 2013; own unpublished experiences).
When MCAD is suspected, therapies that strongly activate
the immune system (e.g., vaccinations with live vaccines
or autohemotherapy) must be given with caution (espe-
cially if similar therapies were previously already poorly
tolerated), as such interventions sometimes dramatically
worsen MCAD acutely and/or chronically.
Any drug can induce intolerance symptoms in the individ-
ual MCAD patient. In some MCAD patients, the disease cre-
ates such remarkable states of not only constitutive MC acti-
vation but also aberrant MC reactivity that such patients un-
fortunately experience a great propensity to react adversely to
a wide variety of medication triggers. Those MCAD patients
begin demonstrating (either acutely or subacutely) odd/unusu-
al/weird/strange/bizarre/unexpected symptoms soon after be-
ginning newmedications. It is very important to note that such
patients often demonstrate even a greater propensity to react to












X Damaj et al. 2008
Gruson et al. 2013




Multiple X (X) (X) Alexandrakis et al. 2003
Kempuraj et al. 2006
Min et al. 2007
Finn and Walsh 2013R
Weng et al. 2012
Lee et al. 2015
Weng et al. 2015
Miltefosine Raft modulator X (X) Weller et al. 2009
Maurer et al. 2013R
Mepolizumab IL-5 antibody X Otani et al. 2012
Rituximab CD20 antibody X Borzutzky et al. 2014
Ruxolitinib JAK X X Yacoub and Prochaska
2016
Kvasnicka et al. 2014
Cannabinoids Agonists at the
cannabinoid receptors
X De Filippis et al. 2008
Frenkel et al. 2015
Own unpublished
experiences
Methylene blue Guanylyl cyclase inhibitor Anaphylaxis treatment Rodrigues et al. 2007
Evora and Simon 2007R
Pimecrolimus Calcineurin inhibitor X Cutaneous symptoms;
(mice)
Ma et al. 2010
Correia et al. 2010
Everolimus mTOR no effect Parikh et al. 2010
Ribavirin Possibly suppression of activated
retroviral elements in the
genome which may be
involved in the development of
the somatic mutations in KIT
and other proteins




R review article (further references therein)
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medication excipients (i.e., fillers, binders, dyes, preserva-
tives) than to the active ingredients. When the patient tries
one or more alternative formulations of a medication with
the same active ingredient but sharing as few as possible (pref-
erably none) of the excipients in the offending formulation,
the patient may discover the medication to be at least tolerable
and perhaps even quite effective. Furthermore, such a scenario
obviously provides the patient (and physician and pharmacist)
a great opportunity to identify one or more of the specific
excipients which are triggering abnormal reactivity in the pa-
tient’s dysfunctional MCs, and it is those specific excipients—
not the medication as a whole—that should be added to the
patient’s allergy list and screened against all present medica-
tions being taken by the patient and against all future medica-
tions proposed for the patient. An MCAD patient’s physician
would be wise to not assume, just because an excipient is very
widely used in many medication products and appears innoc-
uous and well tolerated in the vast majority of patients, that the
same excipient will necessarily be tolerated well in MCAD
patients (unpublished observation of the authors). Sometimes
the specificity of the reaction is quite extraordinary. For ex-
ample, patients who react to wood-based microcrystalline
cellulose might tolerate cotton-based microcrystalline cellu-
lose without any difficulty at all, or vice versa. In some cases,
the pharmacist is unable to identify alternative commercially
available formulations sharing few to none of the excipients in
the offending formulation, and in those cases, a compounding
pharmacist may need to be engaged to identify/develop a
custom-compounded formulation the patient can tolerate.
(There can be geographic and financial challenges in
acces s ing compound ing pha rmac ie s , though . )
Occasionally, MCAD patients may be so remarkably
reactive to such a wide range of excipients that they
can only tolerate a given medication when provided as
pure drug salt, reconstituted in water (without preserva-
tives). Intolerance symptoms can be mediated by IgE
antibodies, though this scenario appears to be rare since
the symptoms are usually not ameliorated by the anti-
IgE monoclonal antibody omalizumab (unpublished ob-
servation, G.J. Molderings). Alternatively, they may be
mediated by IgG antibodies, raising the question of
whether gamma globulin (if itself tolerable) might be a
helpful adjunct therapy in such patients (perhaps by di-
rectly targeting the MC surface’s IgG receptors or via
Table 12 Compilation of drugs associated with a high risk of release of mediators from mast cells and their therapeutic alternatives (compiled from
Mousli et al. 1994; Sido et al. 2014; Afrin et al. 2015b; McNeil et al. 2015)
Substance group Drugs with proven or theoretical high risk




















Bupropion Amitriptyline, doxepine, clomipramine, maprotiline
Selective serotonin reuptake inhibitors All
Anticonvulsive agents Carbamazepine, topiramate Clonazepam
Opioid analgesics meperidine, morphine, codeine remifentanil, alfentanil, fentanyl, oxycodon, piritramid
Peripheral-acting analgesics Acidic non-steroidal anti-inflammatory
drugs such as ASS or ibuprofen
Paracetamol, metamizol




prefer amide-Type, e.g., bupivacaine
Peptidergic drugs Icatibant, cetrorelix, sermorelin, octreotide,
leuprolide
X-ray contrast medium Iodinated contrast medium
Gadolinium chelate
Non-ionic contrast media: iohexol, iopamidol, iopromida,
ioxilan, ioversol, idolatran, iodixanol
Plasma substitutes Hydroxyethyl starch
Gelatine
Albumin solution, 0.9 %-NaCl solution, Ringer’s solution
Cardiovascular drugs ACE inhibitors
ß-Adrenoceptor antagonists
Sartans, calcium channel antagonists, ivabradine, and much else
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indirect pathways). Recently, a MC-specific receptor
termed MRGPRX2 has been identified which appears
to be crucially involved in pseudo-allergic drug reac-
tions (McNeil et al. 2015; Seifert 2015).
Drugs which should not be used in MCAD
Several drugs have the ability to trigger MC mediator release.
A compilation of drugs known to be associated with a high
risk of release of mediators from MCs is given in Table 12.
However, there often are therapeutic alternatives to these
drugs (Table 12).
Conclusions and future perspectives
The therapeutic management of individuals with MCAD is
complex and requires reviewing the entire spectrum of symp-
toms. The paucity of randomized, controlled studies makes
treatment of refractory disease challenging and requires pa-
tience, persistence, and a methodical approach on the parts
of both patient and managing provider(s). Delayed control of
the symptoms may increase morbidity. Effective therapy often
consists simply of antihistamines and MC-stabilizing com-
pounds supplemented with medications targeted at specific
symptoms and complications (Table 13). Current treatment
options for refractory disease are based mainly on
Table 13 Schematic summary of
selected potential targets of
pharmacological interventions in
MCAD
Targets of drugs located in the
plasma membrane
Histamine H1 receptor H1-antihistamines
Histamine H2 receptor H2-antihistamines
CB1/CB2 cannabinoid receptors Cannabinoids
cysLTR1 leukotriene receptor CysLTR1 antagonists, e.g., montelukast
ß-Adrenoceptor ß-Sympathomimetics
EP2 receptor EP2 receptor agonist, e.g., butaprost
Chemokine receptors Chemokines




Targetting released mast cell
mediators
Tryptase Tryptase inhibitor, e.g., nafamostat
Chymase Chymase inhibitor, e.g., BCEAB (4-[1-[bis-(4-methyl-pheny)-methyl]-3-
(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid)








Histamine Histidine decarboxylase inhibition, e.g., by vitamin C
Leukotrienes 5-Lipoxygenase inhibitors, e.g., zileuton
Prostaglandins Cyclooxygenase inhibitors, e.g., acetylsalicylic acid, etoricoxib
Inhibition of cytosolic pathways
Signaling pathways containing
protein kinases
Inhibitors of protein kinases (see Table 8)
mTOR pathway e.g., rapamycin, everolimus
Apoptotic pathways Stimulation of apoptosis by, e.g., ABT-737, obatoclax
Intranuclear targets
Histone deacetylase Histone deacetylase inhibitors, e.g., vorinostat
DNA methylation Demethylating agents, e.g., 5-azacytidine, 5-aza-2′deoxycytidine
DNA Nucleoside analog cladribine
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observational studies and case reports. Until larger random-
ized, controlled trials become available to give more guidance
on therapy for refractory disease, clinicians should use the
available data in conjunction with their clinical expertise and
the adverse effect profile of the available drugs to make treat-
ment decisions. More research is certainly needed to better
understand MCAD pathobiology, in particular to determine
which deregulated genes contribute to a specific symptom or
symptom cluster. The greatest challenge in translational re-
search for the discovery of new rational therapies requires a
highly interactive interdisciplinary approach engaging basic
science labs and clinicians. Understanding of the key compo-
nents might hasten the progress of novel treatment for all these
devastating MCAD phenotypes.
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